Randomized Trial of Intravenous Heparin
Versus Recombinant Hirudin for Acute Coronary Syndromes
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lla Investigators
Background Although intravenous heparin is routinely used in the treatment of patients with acute coronary syndromes, this anticoagulant requires antithrombin III as a cofactor, has no affinity to clot-bound thrombin, and is bound or inactivated by several plasma proteins and platelet factor 4. Recombinant hirudin, the prototypic direct thrombin inhibitor, has been demonstrated in pilot studies to yield improved angiographic and clinical outcomes compared with heparin. We compared these two antithrombins in a large-scale randomized trial.
Methods and Results At 275 participating hospitals in 12 countries, patients within 12 hours from the onset of ischemic chest discomfort with an abnormal ECG were randomly assigned to receive a 72-to 120-hour infusion of heparin (5000-U bolus and 1000-to 1300-U/h infusion, adjusted to activated partial thromboplastin time (APTT) of 60 to 90 seconds or hirudin (0.6-mg/kg bolus and 0.2-mg/kg per hour infusion without aPTT adjustment) on a double-blind basis. Although recruitment of 12 000 patients was planned, the trial was stopped earlier because of an excess of intracerebral hemorrhagic events after 2564 patients were enrolled. The overall incidence of hemorrhagic stroke tended to be higher for patients receiving hirudin (1.3%) compared with heparin (0.7%), P=.11, but the incidence was significantly higher in ur contemporary approach to the treatment of patients with acute coronary syndromes, including unstable angina, non-Q-wave myocardial infarction (MI), and ST-segment elevation infarction, is to administer intravenous heparin along with acetylsalicylic acid.1-3 Heparin is not an ideal antithrombotic agent; it requires antithrombin III as a cofactor, does not have affinity for clot-bound thrombin, and is bound or inactivated by plasma proteins and platelet factor 4.4.5 Because of these theoretical deficiencies, direct thrombin inhibitors-which bind to the catalytic site of thrombin, bind to thrombin in clot, and are resistant to agents that degrade heparin-have been studied in patients with acute coronary syndromes. The prototypic direct thrombin inhibitor is hirudin, a 65-amino-acid peptide derived from the medicinal leech (Hirudo medicinalis), which represents the most potent known naturally occurring anticoagulant and has now been made available in clinically useful quantities through recombinant technology.6-8 Hirudin has been compared with heparin in pilot studies with conjunctive thrombolytic therapy9J0 and in patients with unstable angina and non-Q-wave MI. 5 These results have been encouraging, suggesting the potential for improved efficacy of preventing coronary artery thrombosis or facilitating thrombolysis without an increased hemorrhagic risk.59"10,11 Hirudin also has yielded a more consistent effect on anticoagulation, requiring substantially less adjustment to achieve a stable anticoagulant effect. [9] [10] [11] All events of death, stroke, and MI were reviewed by an independent adjudication committee blinded to therapy assignment. The trial's sample size was calculated to be 12 000 patients assuming one third of patients entered in the STsegment elevation stratum, two thirds of patients entered in the non-ST-segment elevation stratum, and an overall event rate of 8.5% with a 20% reduction by recombinant hirudin (a, 0.025; f3, 0.10) .
A data and safety monitoring committee was convened to review the data after the first 1000 patients were entered and to provide continued surveillance as necessary in the event of untoward bleeding events. If the data and safety monitoring committee recommended early cessation, the steering committee reviewed the recommendation and made the final decision.
Members of the steering committee or data and safety monitoring committee were free of conflicts of interest, which included any financial linkage, such as equity, honoraria, consultancy, or travel reimbursement, with the primary sponsor (CIBA-GEIGY Corp).
Intracranial hemorrhage was defined as an acute new neurological deficit resulting in death or lasting >24 hours, classified by a neurologist, with a computed tomographic scan, magnetic resonance imaging scan, or autopsy demonstrating hemorrhage. All cases were reviewed and confirmed by a committee including an expert neurologist. Only the intracranial hemorrhage outcome data are included in this report. Final efficacy data, including detailed secondary outcomes, will be the subject of a future report. Furthermore, the final clinical baseline characteristics and treatment and outcome data will be available only after extensive quality-control procedures have been completed. These results, except for the verification of stroke cases, represent preliminary information that will be updated and completed in the final study report.
Continuous data were descriptively summarized using means and SDs and also medians with 25th and 75th percentiles. Discrete variables were summarized in terms of frequencies and percentages. Intracerebral hemorrhage incidence rates were expressed as percentages accompanied by 95% confidence intervals and were compared between treatment groups by use of the x2 test or Fisher's exact test. Treatment comparisons were performed according to the intention-totreat principle. All reported P values are two-tailed. The incidence of intracerebral hemorrhage was also compared with the corresponding rate in the GUSTO I trial in which more than 31 000 patients received thrombolytic therapy and intravenous heparin.3
Results
The trial was initiated September 1, 1993, and terminated earlier than planned on April 8, 1994 , because of an excess of intracerebral hemorrhage. Selected baseline characteristics for the 2564 patients enrolled are summarized in Table 1 and compared with the GUSTO I patients receiving intravenous heparin as a reference group to demonstrate their increased age (P<.001) and preponderance of women (P<.001) compared with the patients enrolled in the previous large-scale trial.
As shown in Table 2 , the overall incidence of hemorrhagic stroke was increased, albeit not a statistically significant difference, for hirudin compared with heparin: 17 of 1273 patients (1.3%; 95% CI, 0.7% to 2.0%) versus 9 of 1291 patients (0.7%; 95% CI, 0.2% to 1.2%), P=.11. All but 3 of the 26 intracerebral hemorrhages occurred in patients who also received thrombolytic therapy such that the incidence of intracerebral hemorrhage with thrombolytic therapy and conjunctive antithrombin therapy was 1.8% (1264 patients) compared with 0.3% (1168 patients) for patients not receiving thrombolytics (P<.001). The 3 patients who did not receive thrombolytic therapy but did experience intracerebral hemorrhage all were in the hirudin group. Thus, there was a trend of increased hemorrhagic stroke among nonthrombolytic patients in the hirudin group (0 of 599 patients for heparin versus 3 of 569 patients receiving hirudin, 0.5%; 95% CI, 0% to 1.1%), P=. tValues below the mean±SD represent the 25th percentile, median, and 75th percentile.
shown in Table 2 , in GUSTO IIa, the hemorrhagic stroke rates were higher after thrombolytic therapy with both heparin and hirudin than the hemorrhagic stroke rates of patients treated with thrombolytic therapy and intravenous heparin in the GUSTO I trial. Furthermore, there was a high rate of intracerebral hemorrhage for both thrombolytic agents, which tended to be higher for streptokinase (2.9%) than for TPA (1.4%), P=0.06. Stroke with thrombolytics and hirudin tended to occur slightly earlier after enrollment than with heparin, although the differences were not significant (8 versus 17 hours [medians] , P=.99). The baseline variables for the 26 patients with hemorrhagic stroke are presented in Table 3 and compared with the event-free cohort. Up to this point, it remained unclear whether the aPTT, an in vitro measure of anticoagulation, represented a significant risk factor for intracranial hemorrhage. Furthermore, because of the distinct effects of hirudin on thrombin relative to heparin, it was uncertain whether the aPTT value after hirudin therapy had a similar meaning as that with heparin. The finding that an elevated aPTT was a significant risk factor for hemorrhagic stroke has several practical implications.
Discussion
First, in the early hours after thrombolytic therapy, there is a significant anticoagulant effect caused by the generation of plasmin, proteolytic effects on coagulation factors, and fibrinogen breakdown. This anticoagulant effect is more extensive with streptokinase than with TPA. '8,19 It is during this time frame when there may be an increased liability from the aggressive heparin and antithrombin therapies that are co-administered with thrombolytics, evidenced in the current study by the very early occurrence of intracerebral hemorrhage in the group of patients receiving thrombolytic therapy and hirudin.
Second, serial monitoring of the aPTT value appears to be warranted during antithrombin therapy, as upward deviation from the target range of 60 to 85 seconds is linked with a higher rate of catastrophic hemorrhage. It remains unclear what the preferred range of aPTT should be, and this is further complicated by the multiplicity of methods for assessing this measure that are ues as a function of the reagents and instruments of testing. Third, our data suggest that the aPTT derived from hirudin therapy is associated with risks very similar to those of heparin, such that the data from this trial for the first time indicate a need to monitor and titrate hirudin therapy, just as is conventionally done with heparin, and to be concerned when the aPTT level exceeds 100 seconds. In a pilot study for the current project, it was demonstrated that, at matched aPTT targets for heparin and hirudin, there was increased inhibition of thrombin activation and more evidence of culprit vessel clot lysis in patients with unstable angina.1" Unlike the safety findings that suggest similar risks with heparin and hirudin as a function of elevated aPTT, the pilot findings suggest that there may be heightened efficacy for hirudin compared with heparin in spite of an equivalent ex vivo anticoagulant effect. Of note, the effects on clot lysis for hirudin did not demonstrate a dose-response curve. Although it was assumed that higher doses of hirudin would have more pronounced effects, more recent data from multiple studies performed to date5,9,10,11,20 suggest a step-function rather than dose-response curve, with no clear-cut benefit of increasing the hirudin dose beyond the infusion level of 0.1 mg/kg per hour.
Fourth, the increased rate of intracerebral hemorrhage with streptokinase and heparin or hirudin, up to fourfold that documented in GUSTO I, raises the issue of need for and risk of conjunctive antithrombin therapy with this thrombolytic agent. In GUSTO I there was no difference in outcome for streptokinase with intravenous heparin compared with subcutaneous heparin; in previous large trials there have been no differences between streptokinase and subcutaneous heparin in contrast to no heparin.21, 22 The potential simplicity of streptokinase without the need for conjunctive antithrombin therapy has been advocated,23 but there are conflicting data, which include facilitation of the clinical benefits of streptokinase with Hirulog13 and improved patency at 5 to 7 days after intravenous heparin and streptokinase compared with subcutaneous heparin.15 Thus, the increased rate of hemorrhagic stroke associated with the use of streptokinase in the current trial deserves further study, particularly in light of the extensive prior trial experience with streptokinase that documents its safety with respect to hemorrhagic strokes. 5, 21, 22 On the basis of the findings, the trial has been re-initiated at lower doses of heparin (the same as used in GUSTO I) and hirudin (0.1-mg/kg bolus and 0.1-mg/kg per hour infusion). The aPTT target range has been adjusted downward (back to 60 to 85 seconds), and recombinant hirudin as well as heparin will be titrated so as to avoid high aPTT values. Both agents will be down-titrated for marked aPTT prolongation in the early (6-and 12-hour) determinations. Because it remains uncertain whether the higher risk population, with older patients and more women, may at least in part have accounted for the excessive risk in the current project, we have added the exclusion of prior stroke and uncontrolled hypertension, the latter defined by systolic blood pressure >200 mm Hg. In addition, because clearance of hirudin relies on intact renal function, and currently in use, each yielding somewhat different valat least two hemorrhagic strokes occurred in the setting of renal dysfunction, there will be increased attention to serum creatinine at the time of enrollment, with exclusion of patients with creatinine >2.0 mg/dL, and fluxes of renal dysfunction during therapy. With these modifications, we hope to test the original thrombin hypothesis without an undue hazard of serious bleeding complications. Our findings emphasize the importance of safety studies following and complementing angiographic studies.
